FGFR1 and prostate cancer: Knockdown of CX3CR1 or blockage of CX3CR1 by different chemical inhibitors (AZD8797 and JMS-17-2) effectively suppressed FGFR1 activation and the formation of prostate cancer organoids (Figure 8).